Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer
  • CME

Credits Available
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: September 11, 2020 Expiration: September 10, 2021
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Daiichi Sankyo, Inc.
Adam M. Brufsky, MD, PhD
Program Director
Thomas Bachelot, MD, PhD
person default
Cristina Saura, MD, PhD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate recent practice-changing advances in the treatment of HER2-positive MBC
  • Identify new and emerging therapies for third line and beyond for HER2-positive MBC
  • Assess clinical trial results for novel HER2-directed and targeted therapies in this setting

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Adam M. Brufsky, MD, PhD

Professor of Medicine
Hematology/Oncology
University of Pittsburgh School of Medicine
Associate Chief, Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Adam M. Brufsky, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Daiichi, Puma, Roche, and Seattle Genetics.

Faculty

Cristina Saura, MD, PhD

Medicine and Surgery/Medical Oncology
Universidad Universitat Autònoma Barcelona and Vall d’Hebron Institute of Oncology (VHIO)
Head, Breast Cancer Program
Medical Oncology
Vall d’Hebrón University Hospital
Barcelona, Spain

Cristina Saura, MD, PhD, has disclosed she has received consulting fees or received travel grants from AstraZeneca, Celgene, Daiichi Sankyo, Eisai, F. Hoffmann-La Roche Ltd, Genomic Health, Merck, Novartis, Pfizer, Philips HealthWorks, Pierre Fabre, prIME Oncology, Puma, Seattle Genetics, Sanofi, and Synthon.
Thomas Bachelot, MD, PhD

Chair, Unicancer Breast Group - UCBG
Breast Cancer Unit
Medical Oncology
Centre Leon Bérard
Lyon, France

Thomas Bachelot, MD, PhD, has disclosed that he has received consulting fees from Roche, Novartis, AstraZeneca, Pfizer, and Seattle Genetics.

Staff

Justine Stanley

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has disclosed that his spouse or partner has ownership interest in AstraZeneca.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for global medical oncologists and other healthcare providers who care for patients with breast cancer.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to integrate new and emerging therapies into treatment for HER2-positive breast cancer treatment.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 11, 2020, through September 10, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Novel Anti-HER2 Monoclonal Antibody (4 minutes)
  • CME

Loading...
Thomas Bachelot, MD, PhD, provides an update of key trial data on margetuximab in HER2-positive advanced breast cancer.
Adam M. Brufsky, MD, PhD
Program Director
Thomas Bachelot, MD, PhD
person default
Cristina Saura, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: September 11, 2020 Expiration: September 10, 2021

This program is divided into short segments that you can review from the activity landing page.

Related Content

On-demand webcast from a live Clinical Care Options (CCO) webinar with global expert perspectives on CDK4/6 inhibitors for early-stage HR+/HER2- breast cancer

Javier Cortes, MD, PhD Stephen R. D. Johnston, MA, FRCP, PhD Sara Tolaney, MD, MPH Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 21, 2021 Expired: July 20, 2022

From Clinical Care Options (CCO), video of pharmacist discussion of recently approved agents targeting HER2 and TROP2 for metastatic cancers

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Allison Butts, PharmD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: July 20, 2021 Expired: July 19, 2022

Gain key clinical insights quickly with this short slideset from CCO on the latest data on treatment for patients with HR+/HER2- early breast cancer

Javier Cortes, MD, PhD Stephen R. D. Johnston, MA, FRCP, PhD Sara Tolaney, MD, MPH Released: July 9, 2021

Experts assess recurrence risk and use CDK4/6 inhibitors for HR+/HER2- early breast cancer in this on-demand webcast from a live Clinical Care Options (CCO) webinar

Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Sara Tolaney, MD, MPH Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 9, 2021 Expired: July 8, 2022

Video Chapters


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue